Lewis B E, Leya F S, Wallis D, Grassman E
Department of Cardiology, Loyola University Medical Center, Maywood, Illinois 60153.
Can J Cardiol. 1994 Jun;10(5):559-61.
The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies. Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined. The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.
尽管有许多经验性治疗方法，但肝素诱导的血栓形成相关的发病率和死亡率仍然很高。Ancrod已成功用于预防需要短暂再次暴露于肝素的肝素诱导血小板聚集患者发生血栓形成，但其在已发生血栓形成综合征患者中的疗效尚不明确。作者报告了1例Ancrod治疗肝素诱导血栓形成失败的病例。
